Povorcitinib

Povorcitinib
Clinical data
Other namesINCB-054707
Drug classDisease-modifying antirheumatic drug
ATC code
  • None
Identifiers
  • 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H22F5N7O
Molar mass507.469 g·mol−1
3D model (JSmol)
  • CC1=C(C(=NN1)C)C2=CN(N=C2)C3(CN(C3)C4=C(C=C(C(=C4)F)C(=O)N[C@@H](C)C(F)(F)F)F)CC#N
  • InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1
  • Key:MSGYSFWCPOBHEV-AWEZNQCLSA-N

Povorcitinib is an investigational new drug that is being evaluated for the treatment of the skin conditions hidradenitis suppurativa. It is a JAK1 inhibitor.

Society and culture

In September 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Povofortay, intended for the treatment of hidradenitis suppurativa. The applicant for this medicinal product is Incyte Biosciences Distribution.

Names

Povorcitinib is the international nonproprietary name.

References

  1. 1 2 3 4 "Povofortay EPAR". European Medicines Agency (EMA). 18 September 2026. Retrieved 17 October 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ↑ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.

Further reading